<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02618733</url>
  </required_header>
  <id_info>
    <org_study_id>14-218</org_study_id>
    <nct_id>NCT02618733</nct_id>
  </id_info>
  <brief_title>Comparing Ticagrelor Versus Clopidogrel on Microcirculation</brief_title>
  <acronym>PLEIO</acronym>
  <official_title>A Prospective Randomized Controlled Clinical Trial of Comparing ticagreLor Versus clopidogrEl on mIcrocirculation in Patients With Acute cOronary Syndrome Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biotronik SE &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dong-A University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently, data (PLATO) from an AstraZeneca study of platelet inhibition and patient outcomes,&#xD;
      a Phase III pivotal efficacy and safety study with a duration of up to 12 months comparing&#xD;
      ticagrelor 90 mg twice daily dosing to clopidogrel 75 mg once daily dosing in acute coronary&#xD;
      syndrome patients on ASA background, have demonstrated superiority of ticagrelor over&#xD;
      clopidogrel in the prevention of fatal and non-fatal cardiovascular events. Currently, the&#xD;
      mechanism for this mortality reduction remain uncertain. One hypothesis is a adenosine&#xD;
      mediated theory that ticagrelor has been shown to enhance adenosine-induced vasodilation.&#xD;
      Several experimental and clinical studies support the hypothesis that adenosine could reduce&#xD;
      cardiac ischaemia reperfusion damage. Moreover, recent study has demonstrated that ticagrelor&#xD;
      enhances adenosine-induced coronary vasodilatory responses in healthy humans. However, there&#xD;
      are no available data on coronary circulation effects after chronic treatment of ticagrelor&#xD;
      in patients with ACS who have altered resting coronary blood flow dynamics due to advanced&#xD;
      coronary artery disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, randomized, open-label, active controlled study with two&#xD;
      parallel study groups.&#xD;
&#xD;
      For inclusion in the study subjects should fulfill the following criteria:&#xD;
&#xD;
        1. Provision of informed consent prior to any study specific procedures&#xD;
&#xD;
        2. Female or male aged 20-85 years&#xD;
&#xD;
        3. All patients with ACS scheduled for PCI will be eligible, assuming their ability to&#xD;
           understand the character and individual consequences of participation as well as giving&#xD;
           written informed consent.&#xD;
&#xD;
        4. Be able to understand and comply with the requirements of the study, as judged by the&#xD;
           investigator.&#xD;
&#xD;
      To investigate the effects of ticagrelor on coronary microcirculation, IMR will be measured&#xD;
      twice, 6 months apart in the same lesion, compared with clopidogrel.&#xD;
&#xD;
      The IMR is defined as simultaneously measured distal coronary pressure divided by the inverse&#xD;
      of the thermodilution-derived hyperaemic mean transit time (Tmn), or more simply, distal&#xD;
      coronary pressure multiplied by the Tmn.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">December 31, 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Index of microcirculatory resistance using 0.014-in coronary pressure wire</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fractional flow reserve using 0.014-in coronary pressure wire</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary flow reserve using 0.014-in coronary pressure wire</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor 90mg, twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel 75mg, once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>90mg, twice a day</description>
    <arm_group_label>Ticagrelor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>75mg, once a day</description>
    <arm_group_label>Clopidogrel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of informed consent prior to any study specific procedures&#xD;
&#xD;
          -  All patients with ACS scheduled for PCI will be eligible, assuming their ability to&#xD;
             understand the character and individual consequences of participation as well as&#xD;
             giving written informed consent.&#xD;
&#xD;
          -  Be able to understand and comply with the requirements of the study, as judged by the&#xD;
             investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of intracranial bleeding&#xD;
&#xD;
          -  Severe hepatic impairment&#xD;
&#xD;
          -  Active pathologic bleeding&#xD;
&#xD;
          -  Hypersensitivity to ticagrelor or any of the excipients&#xD;
&#xD;
          -  Liver cirrhosis greater than or equal to Child class B&#xD;
&#xD;
          -  Decreased serum platelet level (≤ 100,000/uL)&#xD;
&#xD;
          -  Life expectancy ≤ 1 year&#xD;
&#xD;
          -  Need for chronic oral anticoagulant therapy&#xD;
&#xD;
          -  Patients with known bleeding diathesis or coagulation disorder&#xD;
&#xD;
          -  History of previous intracranial bleed at any time, gastrointestinal bleed within the&#xD;
             past 6 months, or major surgery within 30 days.&#xD;
&#xD;
          -  Ischemic stroke within the previous 14 days&#xD;
&#xD;
          -  Renal failure requiring dialysis or anticipated need for dialysis during the course of&#xD;
             the study&#xD;
&#xD;
          -  Concern for inability of the patient to comply with study procedures and/or follow up&#xD;
&#xD;
          -  Unable to give informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyungil Park, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dong-A University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Internal Medicine,Dong-A University College of Medicine</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>November 25, 2015</study_first_submitted>
  <study_first_submitted_qc>November 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2015</study_first_posted>
  <last_update_submitted>February 2, 2018</last_update_submitted>
  <last_update_submitted_qc>February 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dong-A University</investigator_affiliation>
    <investigator_full_name>Kyungil Park</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 14, 2019</submitted>
    <returned>December 3, 2019</returned>
    <submitted>August 22, 2020</submitted>
    <returned>September 8, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

